---
figid: PMC12235269__EXCLI-24-638-g-003
figtitle: Fig. 3. JAK-STAT signalling pathway and JAK inhibitors in ulcerative colitis
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC12235269
filename: EXCLI-24-638-g-003.jpg
figlink: /pmc/articles/PMC12235269/figure/F3/
number: F3
caption: 'The binding of cytokines to their receptors activates specific JAKs that
  are bound to the intracellular domain of the receptors. Consequently, the transcription
  factor STAT is phosphorylated, and phosphorylated STAT moves into the nucleus to
  regulate gene expression. Tofacitinib acts on all JAKs, filgotinib acts specifically
  on JAK1, and upadacitinib acts on JAK1 and partially on JAK2.Abbreviations: EPO,
  erythropoietin; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte
  macrophage colony stimulating factor; IFN, interferon; IL, interleukin; JAK, janus
  kinase; LIF, leukaemia inhibitory factor; OSM, oncostatin M; TYK, tyrosine kinase'
papertitle: 'Unraveling the complexity of ulcerative colitis: insights into cytokine
  dysregulation and targeted therapies'
reftext: Yuta Shimomori, et al. EXCLI J. 2025;24(NA).
year: '2025'
doi: 10.17179/excli2025-8374
journal_title: EXCLI Journal
journal_nlm_ta: EXCLI J
publisher_name: Leibniz Research Centre for Working Environment and Human Factors
keywords: ulcerative colitis | cytokines | targeted therapy | innate immune cells
  | adapted immune cells
automl_pathway: 0.9397234
figid_alias: PMC12235269__F3
figtype: Figure
redirect_from: /figures/PMC12235269__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12235269__EXCLI-24-638-g-003.html
  '@type': Dataset
  description: 'The binding of cytokines to their receptors activates specific JAKs
    that are bound to the intracellular domain of the receptors. Consequently, the
    transcription factor STAT is phosphorylated, and phosphorylated STAT moves into
    the nucleus to regulate gene expression. Tofacitinib acts on all JAKs, filgotinib
    acts specifically on JAK1, and upadacitinib acts on JAK1 and partially on JAK2.Abbreviations:
    EPO, erythropoietin; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte
    macrophage colony stimulating factor; IFN, interferon; IL, interleukin; JAK, janus
    kinase; LIF, leukaemia inhibitory factor; OSM, oncostatin M; TYK, tyrosine kinase'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - il7
  - il13
  - il4
  - il21
  - il15
  - ifnphi1
  - il26
  - il10
  - il22
  - il6
  - il11b
  - csf3b
  - csf3a
  - epoa
  - tpo
  - thpo
  - m17
  - osm
  - jak3
  - jak2b
  - tyk2
  - IL7
  - LINC02605
  - IL4
  - IL2
  - IL22
  - IL21
  - IL15
  - IL9
  - IFN1@
  - IFNA1
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - IL26
  - IL10
  - IL13
  - IL6
  - IL11
  - IL27
  - IL31
  - IL12A
  - IL12B
  - IL37
  - IL23A
  - CSF3
  - IL3
  - IL5
  - EPO
  - TIMP1
  - EPX
  - CSF2
  - TPO
  - THPO
  - IL17B
  - IL20
  - IL19
  - LIF
  - OSM
  - CCM2
  - JAK3
  - JAK2
  - TYK2
  - Tofacitinib
---
